

## **MAESTRO TRIAL – FINAL RESULTS**

Gisela L.G. Menezes, MD, PhD













## Angiogenesis





#### How does OA work?



Malignant

Benign



### How does OA work?



0

D

#### How does OA work?





## **Optoacoustic Imaging**









## **MAESTRO - Primary Objectives**

- To assess OA/US's ability to correctly downgrade benign masses classified as BI-RADS 4a and 4b to BI-RADS 3 or 2.
- Sensitivity, specificity, PPV, NPV, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) of CDU and OA/US.



### Why BI-RADS 4a and 4b?

Category	Definition	Probability of Malignancy
0	Needs additional imaging evaluation	NA
1	Normal mammography – back to screening program	0%
2	Benign findings – back to screening program	0%
3	Probably benign – 6-month interval follow-up	≤ 2%
4	Suspicious abnormality – tissue diagnosis (biopsy)	<ul> <li>4a, Low POM (&gt;2% to ≤ 10%)</li> <li>4b, Moderate POM (&gt;10% to ≤ 50%)</li> <li>4c, High POM (&gt; 50% to &lt; 95%)</li> </ul>
5	Highly suggestive of malignancy – tissue diagnosis (biopsy)	≥ 95%
6	Known biopsy-proven malignancy	NA

## **Study Design**

• Prospective, multicenter, and observational study.



 Based on images obtained with OA/US, investigators estimated the probability of malignancy (POM) on a scale from 0% to 100% and, when appropriate, adjusted the BI-RADS classification.



## **Study Design**

- Five OA features were scored (downgrade or upgrade the lesion classification).
- 140 benign and 70 malignant masses were projected.
- Power>80% (2% Type I error).
- Sensitivity and specificity for CDU and OA were calculated. PLR and NLR were also calculated.



# **Results: BI-RADS classification of benign lesions according to CDU and OA (n=146)**

	CDU BI-RADS	
OA BI-RADS	4a (N=119)	4b (N=27)
2	8 (6.7%)	0
3	49 (41.2%)	3 (11.1%)
4a	44 (37.0%)	3 (11.1%)
4b	18 (15.1%)	11 (40.7%)
4c	0	9 (33.3%)
5	0	1 (3.7%)
Downgrade CDU BI-RADs (4a, 4b) to OA BI-RADs (2, 3):		
Downgrade [n/N (%)]	60/146 (41.1%)	
96% CI	(32.7, 49.4)	
P-value [null hypothesis is ≤ 15%]	< 0.0001	



### **Results: BI-RADS classification of malignant lesions according to CDU and OA (n=67)**

	CDU BI-RADS	
OA BI-RADS	4a (N=7)	4b (N=60)
2	1 (14.3%)	0
3	1 (14.3%)	1 (1.7%)
4a	4 (57.1%)	6 (10.0%)
4b	1 (14.3%)	21 (35.0%)
4c	0	30 (50.0%)
5	0	2 (3.3%)
Downgrade CDU BI-RADs (4a, 4b) to OA BI-RADs (2, 3):		
Downgrade [n/N (%)]	3/67 (4.5%)	
96% CI	(0.9, 13.0)	
p-value [null hypothesis is ≥ 10%]	0.0872	



### Results

• CDU sensitivity = 
$$\frac{TP}{TP+FN} = \frac{67}{67} = 100\%$$

• CDU Specificity 
$$= \frac{TN}{TN+FP} = \frac{0}{146} = 0\%$$

• **OA sensitivity** = 
$$\frac{TP}{TP+FN} = \frac{64}{67} = 95.5\%$$

• **OA Specificity** 
$$= \frac{TN}{TN + FP} = \frac{60}{146} = 41.1\%$$

• OA without the estimator : PPV was 42.7% and NPV was 95.2%. PLR was 1.61 and NLR was 0.11



## **Discussion**

- NLR of 0.11 post-test probability lower than the pre-test probability.
- BI-RADS 3 (benign) has a very low POM ( $\leq 2\%$ ).
- The POM of BI-RADS 4a varies from >2% to  $\leq$ 10%.
- A NLR of 0.11 shows that a pre-test probability at the upper end of a 4a lesion (≈10%) can be reduced to a post-test probability of 1.1% by a negative OA examination, allowing the lesion to be downgraded from BI-RADS 4a to 3.



## **Discussion**

- BI-RADS lexicon: Categories 1 or 2 are typically benign (virtually 0% chance of malignancy).
- In 8 cases benign masses were downgraded from BI-RADS 4a to BI-RADS 2.
- The lower end of BI-RADS 4a range (≈2%) can be reduced to a post-test probability of only 0.22%.
- The PPV of category 4b varies from from >10% to  $\leq$ 50%.
- Considering category 4b, a mass with a pre-test probability of 15.6% could be downgraded to BI-RADS 3 (2 categories downgrade). However, lesions with a higher probability of malignancy cannot be downgraded without increasing the FN rates.



## Conclusions

# • 41.1% of benign masses could be downgraded in BIRADS category using OA/US.







## Conclusions

#### • 49.2% of malignant masses could be upgraded with OA/US.





## **Conclusions - Implications for patient care**

- OA improves the distinction between benign and malignant masses compared to CDU alone.
- Benign masses classified as BI-RADS 4a can be downgraded to BI-RADS 3 or 2, potentially minimizing negative biopsies and short interval follow-up imaging exams.
- Potential to lower overall costs related to interventional procedures and short-interval follow-up imaging studies.
- Limitations: 3 false-negatives.







# First false-negative mass: an IDC grade 1 which was downgraded from BI-RADS 4b to BI-RADS 2







# Second false-negative mass: an IDC grade 3 which was downgraded from BI-RADS 4a to BI-RADS 2







# Third false-negative mass: an ILC grade 2 (alveolar variant) which was downgraded from BI-RADS 4a to BI-RADS 3







### **Inclusion Criteria**

- Females  $\geq$  18 years.
- Have a suspicious finding classified by CDU as BI-RADS 4a or 4b.
- Have received recommendation for an image-guided biopsy.





#### **Exclusion Criteria**

• Has a condition that could interfere with the intended field of view (breast implants or tattoos).

• Prior surgery within the same quadrant as the mass to be biopsied.

 Have had prior excisional biopsy within the vicinity of the suspicious mass within the past 18 months.







### **Exclusion Criteria**

- More than 3 masses recommended for biopsy.
- Mass to be biopsied is greater than 3.0 cm in maximum diameter.
- Patient currently has mastitis.
- Patient is pregnant or lactating or planning to become pregnant during study participation.







### **Likelihood Ratios**

- Likelihood ratios are important to assess the value of performing a diagnostic test.
- $PLR = \frac{sensitivity}{1 specificity}$
- $NLR = \frac{1 sensitivity}{specificity}$
- The larger the PLR, the greater the likelihood of disease; the smaller the NLR, the lesser the likelihood of disease.
- These rates are less likely to change with the prevalence of the disorder.
- To use this measure a nomogram (estimators) should be employed or pre-test probabilities should be converted into Odds.

